- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00631852
A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer
Study Overview
Detailed Description
Asian ginseng (Panax ginseng) and its close relative American ginseng (Panax quinquefolium) are perennial aromatic herbs that are widely used in Asian medicine. Ginseng root is used as a tonic thought to increase the body's resistance to stress and fatigue, to increase endurance under heavy physical activity, and to improve well-being in age-related debilitation. Most of the ginseng consumed, even in Asian populations, is American ginseng, and the majority of American ginseng is grown and processed in Wisconsin, with quality and standardization overseen by the Ginseng Board of Wisconsin. Furthermore, in Asian medicine, Asian ginseng (Panax ginseng) and American ginseng (Panax quinquefolium) are common components in herbals used for cancer prevention and treatment. Indeed, retrospective studies have shown that patients who consumed ginseng on a regular basis experienced cancers at a reduced rate, however, breast cancer was not considered. Ginseng has been used medicinally for over 2000 years and there are no substantiated serious adverse effects, and few, if any, non-serious adverse effects. The World Health Organization lists ginseng as a traditional medicine with very low toxicity. Clinical trials have also demonstrated an anti-hyperglycemic action of American ginseng. These studies utilized capsules containing dried, ground Ontario-grown P. qinquefolius L. root. The ground AG root preparation had an onset of action of 40 minutes. They found no significant increase in anti-hyperglycemic action after 40 minutes and no significant increase in anti-hyperglycemic action using 1 gram versus 3 gram dosing.
LEAG is a standardized preparation of lyophilized water-extract of American ginseng root in 250-mg gelatin capsules. The ginseng was purchased through the Ginseng Board of Wisconsin and the lyophilized extract has been certified for percentage of each and total ginsenoside content and screened for safe levels of minerals, metals, and pesticides by ConsumerLab.com, a leading testing service company of dietary supplements.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Illinois
-
Springfield, Illinois, United States, 62702
- Simmons Cancer Institute-SIU School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with cytologically confirmed breast cancer with biopsy showing invasive or non-invasive (DCIS) at least 1.0 cm greatest diameter on imaging
- Surgical patients undergoing lumpectomy, subtotal or total mastectomy
- 18 years of age or greater
- female
- available tissue blocks from diagnostic biopsy
- negative pregnancy test, medical history of surgical sterilization, or 1 year post menopausal
- must be willing to forego surgery for minimum of 5 days
- ability and willingness to sign written consent
- if hypertensive, on stable dose of medication at least 30 days
- if diabetic, well controlled (HbA1C < 8.5 within past 60 days or documented FPG < 140 mg/dl for 3 consecutive days
- ECOG status < 2 or Karnofsky of 60% or greater
Exclusion Criteria:
- previous or current malignancy, excluding non-melanomic skin cancer
- evidence of distant metastatic disease
- history of chemotherapy, biologic or radiotherapy with 6 months of biopsy
- usage of herbal supplements or alternative medications not approved by the FDA within 1 week of starting study drug. LEAG or related ginseng products, and combination products containing ginseng, should be discontinued within 6 weeks of starting study drug
- history of allergic reactions attributed to compounds of similar chemical or biologic composition to LEAG
- history of chronic inflammatory process, including, but not limited to, rheumatoid arthritis and lupus. This includes patients on concurrent systemic steroids or anti-inflammatory medications
- active bleeding or a pathological condition that carries a high risk of bleeding
- any swallowing dysfunction
- uncontrolled intercurrent illness
- poorly controlled diabetes (control indicated with HbA1c < 8.5 within past 60 days or documented fasting blood glucose < 140 mg/dl for three consecutive days)
- known diabetics who have experienced episodes of symptomatic hypoglycemia in the last 6 months are also considered poorly controlled and will be excluded from study participation.
- uncontrolled hypertension (SBP > 140 mmHg or DBP > 90 mmHG)
- pregnant or breast feeding women Women must be willing to use birth control throughout study duration.
- current investigational medications or treatment with an investigational agent within 6 weeks prior to biopsy
- current coumadin therapy or who have been treated with coumadin within the 2 weeks prior to biopsy
- current monoamine oxidase inhibitors treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: American Ginseng root
four, 250mg tablets daily 5-14 days prior to surgery
|
four, 250mg tablets daily 5-14 days prior to surgery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adiponectin
Time Frame: mean of 11.8 days
|
Change from baseline to completion of treatment with LEAG.
|
mean of 11.8 days
|
C Reactive Protein (CRP)
Time Frame: mean of 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean of 11.8 days
|
Hepatocyte Growth Factor (HGF)
Time Frame: mean of 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean of 11.8 days
|
Insulin Like Growth Factor 1 (IGF-1)
Time Frame: mean of 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean of 11.8 days
|
Insulin Like Growth Factor 1 Receptor (IGF-1R)
Time Frame: 10-14 days
|
Mean change from baseline following 10-14 days of treatment with LEAG.
|
10-14 days
|
Interlueken-1- (IL-10)
Time Frame: mean 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean 11.8 days
|
IL-12p40
Time Frame: mean 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean 11.8 days
|
IL-1b
Time Frame: mean 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean 11.8 days
|
IL-1ra
Time Frame: mean 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean 11.8 days
|
IL-2
Time Frame: mean of 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean of 11.8 days
|
IL-23
Time Frame: mean 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean 11.8 days
|
IL-4
Time Frame: mean 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean 11.8 days
|
IL-6
Time Frame: mean 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean 11.8 days
|
IL-8
Time Frame: mean 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean 11.8 days
|
Insulin
Time Frame: mean 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean 11.8 days
|
Leptin
Time Frame: mean 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean 11.8 days
|
MCP-1
Time Frame: mean 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean 11.8 days
|
TGFb1
Time Frame: mean 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean 11.8 days
|
TNFa
Time Frame: mean 11.8 days
|
Mean change from baseline to completion of treatment with LEAG.
|
mean 11.8 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Elizabeth Peralta, M.D., Sutter Health
Publications and helpful links
General Publications
- Peralta EA, Murphy LL, Minnis J, Louis S, Dunnington GL. American Ginseng inhibits induced COX-2 and NFKB activation in breast cancer cells. J Surg Res. 2009 Dec;157(2):261-7. doi: 10.1016/j.jss.2009.05.011. Epub 2009 Jun 6.
- Peralta EA, Brewer AT, Louis S, Dunnington GL. Vitamin E increases biomarkers of estrogen stimulation when taken with tamoxifen. J Surg Res. 2009 May 1;153(1):143-7. doi: 10.1016/j.jss.2008.03.030. Epub 2008 Apr 22.
- Peralta EA, Viegas ML, Louis S, Engle DL, Dunnington GL. Effect of vitamin E on tamoxifen-treated breast cancer cells. Surgery. 2006 Oct;140(4):607-14; discussion 614-5. doi: 10.1016/j.surg.2006.07.007. Epub 2006 Sep 6.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PER-SCCI 07-001.1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
Clinical Trials on American Ginseng root
-
Risk Factor Modification CentreCanadian Institutes of Health Research (CIHR); Ontario Ginseng Growers AssociationCompleted
-
Mayo ClinicNational Cancer Institute (NCI)CompletedCancer Survivor | Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC... and other conditionsUnited States
-
Johns Hopkins UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV/AIDS-associated FatigueUnited States
-
Unity Health TorontoCanadian Diabetes AssociationUnknownDiabetes Mellitus Type 2Canada
-
Network Italiano Cure di Supporto in OncologiaAzienda Ospedaliera di Perugia; Associazione Umbra per la lotta Contro il Cancro and other collaboratorsUnknownBreast Cancer Female | Cancer Related FatigueItaly
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Fatigue | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative NeoplasmsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedFatigue | Unspecified Adult Solid Tumor, Protocol Specific
-
Oregon Health and Science UniversityNational Multiple Sclerosis SocietyCompleted
-
University of ReadingNaturexCompletedCognitive Change | Effects of Ginseng on Cognitive FunctionUnited Kingdom
-
Risk Factor Modification CentreOntario Ginseng Growers Association; Ontario Ministry of Agriculture, Food...Completed